Member Info for technick

And that's just in the UK.... well this could get exciting and we still have a great product after the pandemic, hopefully shareholders are waking up to this

Agree. It should also be relatively low cost at scale compared to the NCYT test. Does anyone know what they charge per kit / test? That would give us some cost / turnover calculation?

The potential here is massive IF Genedrive can deliver both a better high throughout assay to market and a point of care / critical decision portable product to market. Reading up on this most of yesterday (yes I have the time now ;)!) it seems like we have a big benefit over the Novacyt test for high throughput labs. Their kit seems to be separate components for primers and probes and reaction mixes prior to dispensing and the lyophilisation seems to be for shipping not storage. Genedrive's offer is pre-aliquoted so you just add sample, like their cartridges. Why is this important? Because it saves time so you can do more tests per day which is where PHE want to be - 250k tests per day. It removes a major bottle next of preparing plates upfront. Really smart move on Genedrive's part in my opinion. If they can then deliver the same lab test in something like Genedrive, which is already being used at point of care by the US DOD for biothreat and by the NHS for AIHL then wow, you have a test that could be deployed to GPs, hospitals, portable testing vehicles. Long term look at the biothreat cartridge, it tests for lot of different things at the same time. Could their be a COVID19/Influenza AB cartridge next which would confirm longer term if a patient has flu or if COVID is re-emerging? This may die down at the end of the year but testing is still important. And that's just the UK, what about the global demand for the Genedrive products? This really is an interesting time for us Genedrive shareholders!

The market can now see the importance of this company and their products. It’s a shame we are in these time’s but testing is what will allow us to moderate the outbreak. The diagnostic tools after this is over will remain important and genedrive will have the opportunity to deploy many different tests for GP testing. I’ve been a long term holder hear for many years. I’m hoping there are more shareholders here now to realise the potential and the value of this. The time has come.

Andre, behave, directors couldn't sell as they have material information that would prevent it at this time

biscuit, everyone knows you have to make verifiable statements, that's just plc language because all statements have some uncertainty attached to them.

I think that's press misreporting. An antibody based test can not tell you if you have an early infection as the antibodies have not yet developed. Plus, it looks as though most antibody based tests are giving a sensitivity of around 80% which isn't great. A good test will have sensitivities >=90%.

this Guardian link is for the antibody test to identify if you have had COVID-19 in the past, the Genedrive test is a molecular test to say do you have an active infection now. They are for two difference use case scenarios.

Even that 50k shares sold didn’t push the price back, this is only heading upwards by the look of it

re-read the announcement, this is really massive news. Genedrive sweet spots for sure! I think we could easily see much higher share price over the coming weeks. Unlike Novacyt Genedrive would have point of care and lab based tests. Great!!

A second test will also be developed by the Company where it will adapt its formulations to run on the Genedrive® instrument platform to provide a rapid point-of-care SARS-COV-2 test to allow testing outside of the main hospital environment in places such as clinics, intensive care units, or where rapid and accurate testing for SARS-COV-2 might be required. The rationale for the two-stage development is that the testing, logistics, validation, and trial work to provide testing on a turnkey instrument system like Genedrive® takes additional time compared to an agnostic assay format.

Could be true, the underlying technology could be adapted to any antibody based marker I guess... Why would it be better than current lateral flow tests? It could be quantitative I guess?

CTW I think you are correct, Genedrive already being used within the NHS for the antibiotic induced hearing loss test so it has an advantage in already being a known quantity within the NHS. With both a high throughput and a POC platform there is a nice consistency in testing there. Plus, US DOD already using over 100 units and just ordering 500 more, the platform has a lot of credibility. Really nice to see this now getting onto everyones radar and supporting innovation!

Perhaps we are in a better position than Novacyt even though we were a little later to the party, it takes time to pull this together to get to a better product, hats off to the Genedrive team!

Troy, I agree, the benefit of the Genedrive test is the ability to stockpile. They have several technical sweet spots for large scale tests and also point of care tests. If Genedrive can also deploy the test then you can also test critical care workers daily. Now that would be very smart!

maybe the market has woken up to diagnostic companies, we need these companies to develop tests, the more investment the more tests. Genedrive has a lot of potential which is what we say when we all invested in the first place. COVID, HCV, TB, US DOD, hearing loss in children. Blimey there's a lot the Company is going!

Here is my reading of the small print on the Novacyt assay, although the kit is lyophilised, it says storage is at -20C so once its shipped at ambient the assay still needs storing at -20C. So I believe the components are all separate and the enzymes are not lyophilised otherwise they would not need to be stored at -20C! So again as I understand it, the Genedrive assay is pre-dispensed and fully lyophilised meaning it is a technically better solution compered to the Novacyt test.... thoughts?

Does anyone remember what the last broker note said in terms of share price target, I seem to remember it being about 60p... I think recent news should at least set that as a realistic aim? Thoughts?

it's a technically superior test!!!

I don't know if anyone else has picked up on this, the Genedrive assays for COVID are freeze dried and ready to go, as far as I know other platforms need their test kits to be made up before adding the sample, but the Genedrive ones would be 'just add sample'. That would greatly speed the testing process. Congratulations Genedrive!!

Agree validation could be done by Novocyt who have already validated their test... presumably